NRG Oncology/GOG Studies
- The goals of treating recurrent platinum-resistant ovarian cancer are palliative, aimed at reducing symptoms and improving progression free survival. A prospective trial was conducted to determine the prevalence and severity of symptoms, and associated care needs.
- For the approximately 22,000 patients projected to be diagnosed with ovarian cancer in 2015, the vast majority will have epithelial ovarian cancer (EOC) . Maximal cytoreductive surgery and administration of adjuvant or neoadjuvant primary chemotherapy with a platinum and taxane combination regimen have proven to be the two most important factors influencing survival [2–6]. Apart from modifying the dose schedule  and route of administration of the platinum and taxane combination , there have been no new drugs alone or in combination with the platinum and taxane backbone that have resulted in improved overall survival (OS) .
- Changes in cognitive function have been identified in and reported by many cancer survivors. These changes have the potential to impact patient quality of life and functional ability. This prospective longitudinal study was designed to quantify the incidence of change in cognitive function in newly diagnosed ovarian cancer patients throughout and following primary chemotherapy.